Advanced TB Diagnostics

Advanced TB Diagnostics | May 29 - June 2, 2023

Register before May 5^th to receive the discount:

• Students, fellows, and trainees studying in Canada or USA can use code “TB50McGill” for 50% off registration fee of IN-PERSON attendance
• Non-trainees working in Canada or USA can use code “TB25McGill” for 25% off registration fee of IN-PERSON attendance
• ***Note there is no discount for online enrollment.***

COURSE FORMAT

Hybrid. Course will be live to both the in-person and online participants approximately 9:00am-4:00pm (Montreal time) each day May 29 – June 2, 2023. Live content will be recorded.

DESCRIPTION

This advanced course will cover topics in TB diagnostics research and implementation, including pipeline of innovations, critical pathway for new TB tests, impact of new tests on clinical decision-making and therapeutic choices, cost-effectiveness in routine programmatic settings, and impact on patient-important outcomes. The course will also cover meta-analysis, mathematical modeling, and cost-effectiveness studies. Panel discussions will cover topics such as value chain for TB diagnostics development, market analyses, market dynamics, target product profiles, and barriers to scale-up of new diagnostics. Participants will include TB survivors, product manufacturers, donors, product development partnerships, policy makers, academics, clinicians, community advocates, public health implementers and National TB Program managers.

COURSE DIRECTOR

Madhukar Pai, MD, PhD
Canada Research Chair of Epidemiology & Global Health, McGill University
Associate Director, McGill International TB Centre

PREVIOUS COURSE FACULTY

• Adithya Cattamanchi, MD – University of California, San Francisco
• Claudia Denkinger, MD, PhD – Heidelberg University
• Puneet Dewan, MD - Bill & Melinda Gates Foundation
• David Dowdy, MD, PhD – Johns Hopkins University
• Nora Engel, PhD – Maastricht University
• Simon Grandjean Lapierre, MD, MSc - Université de Montréal
• Karen Heichman, PhD- Bill & Melinda Gates Foundation
• Nazir Ismail, MBChB, FC Path (SA), MMed (Micro), DTM&H, PDIC - WHO, Geneva
• Farzana Ismail, NICD, South Africa
• Sandeep Juneja, MBA - TB Alliance, New York
• Mikashmi Kohli, PhD - FIND, Geneva
• Tenzin Kunor - We are TB, USA
• Rhea Lobo - Filmmaker & TB Advocate
• Peter MacPherson, MBChB MPH MRes DTM&H DipHIV MFPH PhD - Liverpool-Wellcome Trust Clinical Research Programme, Malawi
• Ruvandhi Nathavitharana, MBBS – BIMDC Harvard Medical School
• Lele Rangaka, MD, PhD - University College, London
• Camilla Rodrigues, MD - Hinduja Hospital, India
• Morten Ruhwald, MD, PhD – FIND
• Samuel Schumacher, MSc, PhD – WHO, Geneva
• Tom Scriba, DPhil - University of Cape Town
• Karen Steingart, MD, MPH – Cochrane ID Group
• Anita Suresh, MBA - FIND, Geneva
• Cesar Ugarte-Gil, MD, MSc, PhD - Universidad Peruana Cayetano Heredia, Peru
• Wayne Van Gemert, MPH – Stop TB Partnership
• Alice Zwerling, PhD – Ottawa University

Faculty are still being confirmed and there may be changes to the above list.

CONTENT

Diagnosis is one of the biggest gaps in the TB cascade of care. We need better tools for TB diagnosis than what we have today, and we need high quality diagnostic studies to evaluate new tools, and to develop evidence-based policies on TB diagnostics. We need data on outcomes such as accuracy of diagnostic algorithms (rather than single tests) and their relative contributions to the healthcare system, incremental value of new tests, impact of new tests on clinical decision-making and therapeutic choices, cost-effectiveness in routine programmatic settings, and impact on patient important outcomes. Translation of policy into impact requires collecting evidence for scale-up, country-level data on cost effectiveness and feasibility, implementation research, and local decisions on scale-up, delivery and impact assessment. All of these issues will be covered in this advanced course.

OBJECTIVES

By the end of the course, participants will understand:
• Value chain for TB diagnostics development, current pipeline of diagnostics, market dynamics, WHO policies on new diagnostics, and challenges for scale-up
• Designs to evaluate impact of new tests on clinical decision making, therapeutic choices, and patient-important outcomes
• Meta-analyses of diagnostic accuracy studies and GRADE approach to diagnostic policies
• Principles of implementation research, collecting evidence for scale-up, cost-effectiveness analyses and modeling studies in TB diagnostics

TARGET AUDIENCE

• National TB Program managers and National Reference Lab managers
• Clinicians and nurses
• Researchers, students, trainees, fellows and academics involved in TB diagnostics research
• Product manufacturers
• Funding agencies
• Product development partnerships
• Policy makers and public health implementers
• Community advocates and civil society

ENROLMENT

In-person maximum 100 participants.
Online maximum 100 participants.